BioTrillion is a technology company.
BioTrillion has raised $3.0M across 1 funding round.
BioTrillion has raised $3.0M in total across 1 funding round.
BioTrillion is a Medtech AI company that transforms smartphones into powerful, contactless health monitors through its AI-powered platform, BioEngine4D™. It enables users to measure multiple vital signs and digital biomarkers simply by taking a 10-second "HealthySelfie," extracting health metrics from facial and eye features using advanced computer vision and AI. This technology serves both consumers and healthcare stakeholders—such as pharmaceutical companies, payors, and providers—by enabling early disease detection, proactive health monitoring, and data-driven drug development. BioTrillion aims to democratize healthcare access for over 1 billion people worldwide by making health insights affordable, scalable, and accessible anytime, anywhere without the need for additional devices[1][2][4].
Founded in 2018 in San Francisco by Savan Devani, a bioengineer with extensive healthcare investment banking experience, BioTrillion emerged from a personal motivation: Devani’s mother’s late-stage cancer diagnosis highlighted the need for earlier disease detection. This inspired him to leverage his bioengineering background and AI to create a new paradigm in healthcare monitoring. The company has since evolved from R&D to commercialization, securing partnerships with leading pharmaceutical firms and developing a robust IP portfolio with multiple patents protecting its AI-driven digital biomarker technology[5][6][3].
BioTrillion rides the convergence of AI, mobile computing, and digital health trends, capitalizing on the ubiquity of smartphones to scale health monitoring globally. The timing is critical as healthcare increasingly shifts toward preventive, personalized, and remote care models. Market forces such as rising chronic disease prevalence, demand for cost-effective diagnostics, and digital transformation in healthcare favor BioTrillion’s scalable, non-invasive approach. By enabling continuous, real-world physiological data capture, BioTrillion influences the broader ecosystem by empowering patients, enhancing clinical decision-making, and accelerating pharmaceutical innovation[2][4][3].
Looking ahead, BioTrillion is poised to expand its digital biomarker portfolio and deepen commercial partnerships, moving further into mainstream healthcare adoption. Trends shaping its journey include advances in AI, growing acceptance of digital biomarkers, and increasing regulatory support for remote health technologies. As the company scales, its influence may extend beyond individual health monitoring to become a foundational platform for population health management and precision medicine, fulfilling its mission to democratize healthcare globally[3][4][6].
BioTrillion has raised $3.0M in total across 1 funding round.
BioTrillion's investors include Vertex Ventures HC.
BioTrillion has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in August 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2018 | $3.0M Seed | Vertex Ventures HC |